$BFLY

Butterfly Network at Morgan Stanley conference: platform push widens reach

Butterfly Network (BFLY) presented its strategy at Morgan Stanley's conference, shifting from handheld ultrasound to a semiconductor imaging platform. The company reported 20% revenue growth, with $112M in last 12-month revenue, and highlighted partnerships like Midjourney. It aims to expand its addressable market to $250B through its Butterfly Embedded model. The company expects a fourth-generation chip in 2027 to improve image quality and challenge competitors. Management emphasized its strong

Original reporting
Published Sep 15, 2026, 3:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 6:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$BFLY
Bullish
high confidence
Mentioned
$BFLY
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BFLYBullishMed
01

Why it matters

The disclosed $74M Midjourney deal and the platform roadmap provide fresh growth catalysts, shifting investor perception.

02

Market read

New partnership and strategic shift could drive BFLY stock higher and influence the broader med‑tech sector.

03

What to watch

Capital intensity of chip development and potential competition from larger imaging players could limit upside.

Relevance 7/10Novelty 7/10Timing: today

Background

Butterfly Network used the Morgan Stanley Global Healthcare Conference to reposition from handheld ultrasound to a broader imaging platform.

Company-level read

Ticker impact

$BFLYBullishHigh confidence
Context

Butterfly Network announced a new $74M five‑year Midjourney partnership and outlined a platform shift to chips, cloud and AI at the Morgan Stanley healthcare conference.

Expected impact

Potential short‑term price lift on news, with longer‑term upside if platform execution succeeds.

Evidence & confidence

A sizable multi‑year contract and clear strategic roadmap provide concrete growth catalysts.

Market effects

Highlights a trend of medical imaging firms moving toward semiconductor‑based platforms, pressuring traditional ultrasound vendors.

U.S. healthcare technology sector may see increased investor interest.

Partnership with Midjourney and TSMC underscores cross‑border tech collaborations.

Counterpoint

Execution risk remains high; platform rollout could be delayed, and partners may not generate expected recurring revenue.

Key entities

  • Butterfly Network

    Medical imaging device maker transitioning to a semiconductor‑based platform.

  • Midjourney

    AI company entering a five‑year licensing agreement worth at least $74M.

Related articles

$QSIMed

2 Brain-Computer Interface Stocks to Watch While Neuralink Stays Private

Neuralink, a private brain-computer interface (BCI) company, successfully helped a patient with ALS communicate. Investors cannot buy Neuralink, but two public companies, Quantum-Si (QSI) and Butterfly Network (BFLY), are connected to the BCI field. QSI makes research tools and saw a 7x volume spike, while BFLY supplies ultrasound chips to BCI developers like Merge Labs and Bridge Neurotech.

$BFLYHigh

Why is Butterfly Network stock climbing today?

Butterfly Network (BFLY) stock rose 1.6% pre-market after Canaccord Genuity initiated coverage with a Buy rating and $10 target, citing its ultrasound tech and AI capabilities. Analysts highlight new products and partnerships. The stock has seen positive analyst activity, with a consensus target of $11.40. Q3 earnings are due October 29.

$BFLYHigh

Evercore ISI initiates Butterfly Network stock with outperform rating

Evercore ISI initiated coverage on Butterfly Network (NYSE: BFLY) with an outperform rating and $15.00 price target, citing its ultrasound-on-chip technology and growth potential. The firm projects $550M+ revenue by 2030 and positive EBITDA by 2028. BFLY stock has risen 367% over the past year, trading at $9.15 with a $2.44B market cap. Q2 2026 results showed a smaller loss than expected but lower revenue. Needham also initiated coverage with a buy rating and $10.00 target.

$BFLYHighAI 8/10

Why is Butterfly Network stock surging today?

Butterfly Network (BFLY) stock rose 11.5% after Needham initiated coverage with a Buy rating and $10 target, citing its ultrasound tech and Embedded business model. TD Cowen also has a Buy rating and $10 target. BFLY's Q3 revenue grew 39% YoY, with Embedded segment growth and expanding margins. The broader market had minimal impact on BFLY's surge.

$BFLYMed

Butterfly Network (BFLY) Is Up 24.2% After Raising 2026 Guidance And Narrowing Losses - Has The Bull Case Changed?

Butterfly Network (BFLY) shares rose 24.2% after the company reported Q2 2026 revenue of $32.61M and a reduced net loss of $12.91M, and raised 2026 revenue guidance to $119M to $123M. The article cites improving losses and momentum in Embedded partnerships and enterprise point-of-care ultrasound, while noting ongoing cash burn and potential dilution risks.